Genome-Wide Scan and Fine-Mapping of Rare Nonsynonymous Associations Implicates Intracellular Lipolysis Genes in Fat Distributio
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Protection of Insulin‑Like Growth Factor 1 on Experimental Peripheral Neuropathy in Diabetic Mice
MOLECULAR MEDICINE REPORTS 18: 4577-4586, 2018 Protection of insulin‑like growth factor 1 on experimental peripheral neuropathy in diabetic mice HUA WANG, HAO ZHANG, FUMING CAO, JIAPING LU, JIN TANG, HUIZHI LI, YIYUN ZHANG, BO FENG and ZHAOSHENG TANG Department of Endocrinology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, P.R. China Received December 24, 2017; Accepted July 19, 2018 DOI: 10.3892/mmr.2018.9435 Abstract. The present study investigated whether insulin-like the IGF-1-PPP group compared with the IGF-1 group; however, growth factor-1 (IGF-1) exerts a protective effect against no significant difference was observed in the expression neuropathy in diabetic mice and its potential underlying levels of p-p38 following treatment with IGF-1. The results mechanisms. Mice were divided into four groups: Db/m of the present study demonstrated that IGF-1 may improve (control), db/db (diabetes), IGF-1-treated db/db and neuropathy in diabetic mice. This IGF-1-induced neurotrophic IGF-1-picropodophyllin (PPP)-treated db/db. Behavioral effect may be associated with the increased phosphorylation studies were conducted using the hot plate and von Frey levels of JNK and ERK, not p38; however, it was attenuated by methods at 6 weeks of age prior to treatment. The motor nerve administration of an IGF-1R antagonist. conduction velocity (NCV) of the sciatic nerve was measured using a neurophysiological method at 8 weeks of age. The Introduction alterations in the expression levels of IGF-1 receptor (IGF-1R), c-Jun N-terminal kinase (JNK), extracellular signal-regulated An epidemiological survey demonstrated that the prevalence kinase (ERK), p38 and effect of IGF-1 on the sciatic nerve of diabetes in adults ≥18 years old in China was ≤11.6% (1). -
Receptor Activity Modifying Proteins (Ramps) Interact with the VPAC2 Receptor and CRF1 Receptors and Modulate Their Function
British Journal of DOI:10.1111/j.1476-5381.2012.02202.x www.brjpharmacol.org BJP Pharmacology RESEARCH PAPER Correspondence David R Poyner, School of Life and Health Sciences, Aston University, Birmingham, Receptor activity modifying B4 7ET, UK. E-mail: [email protected] ---------------------------------------------------------------- proteins (RAMPs) interact Current address: *Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, 381 with the VPAC2 receptor Royal Parade, Parkville, Victoria 3052 Australia; †Discovery Sciences, AstraZeneca R&D, and CRF1 receptors and Mölndal, Sweden; ‡R&I iMED, AstraZeneca R&D, Mölndal, Sweden. modulate their function ---------------------------------------------------------------- Keywords D Wootten1*, H Lindmark2†, M Kadmiel3, H Willcockson3, KM Caron3, receptor activity-modifying proteins (RAMPs); RAMP1; J Barwell1, T Drmota2‡ and DR Poyner1 RAMP2; RAMP3; VPAC2 receptor; +/- CRF1 receptor; Ramp2 mice; 1 2 School of Life and Health Sciences, Aston University, Birmingham, UK, Department of Lead G-protein coupling; biased Generation, AstraZeneca R&D, Mölndal, Sweden, and 3Department of Cellular and Molecular agonism Physiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA ---------------------------------------------------------------- Received 10 July 2012 Revised 15 August 2012 Accepted 28 August 2012 BACKGROUND AND PURPOSE Although it is established that the receptor activity modifying proteins (RAMPs) can interact with a number of GPCRs, little is known about the consequences of these interactions. Here the interaction of RAMPs with the glucagon-like peptide 1 receptor (GLP-1 receptor), the human vasoactive intestinal polypeptide/pituitary AC-activating peptide 2 receptor (VPAC2) and the type 1 corticotrophin releasing factor receptor (CRF1) has been examined. EXPERIMENTAL APPROACH GPCRs were co-transfected with RAMPs in HEK 293S and CHO-K1 cells. -
Silencing of Phosphoinositide-Specific
ANTICANCER RESEARCH 34: 4069-4076 (2014) Silencing of Phosphoinositide-specific Phospholipase C ε Remodulates the Expression of the Phosphoinositide Signal Transduction Pathway in Human Osteosarcoma Cell Lines VINCENZA RITA LO VASCO1, MARTINA LEOPIZZI2, DANIELA STOPPOLONI3 and CARLO DELLA ROCCA2 Departments of 1Sense Organs , 2Medicine and Surgery Sciences and Biotechnologies and 3Biochemistry Sciences “A. Rossi Fanelli”, Sapienza University, Rome, Italy Abstract. Background: Ezrin, a member of the signal transduction pathway (5). The reduction of PIP2 ezrin–radixin–moesin family, is involved in the metastatic induces ezrin dissociation from the plasma membrane (6). spread of osteosarcoma. Ezrin binds phosphatydil inositol-4,5- The levels of PIP2 are regulated by the PI-specific bisphosphate (PIP2), a crucial molecule of the phospholipase C (PI-PLC) family (7), constituting thirteen phosphoinositide signal transduction pathway. PIP2 levels are enzymes divided into six sub-families on the basis of amino regulated by phosphoinositide-specific phospholipase C (PI- acid sequence, domain structure, mechanism of recruitment PLC) enzymes. PI-PLCε isoform, a well-characterized direct and tissue distribution (7-15). PI-PLCε, a direct effector of effector of rat sarcoma (RAS), is at a unique convergence RAS (14-15), might be the point of convergence for the point for the broad range of signaling pathways that promote broad range of signalling pathways that promote the RAS GTPase-mediated signalling. Materials and Methods. By RASGTPase-mediated signalling (16). using molecular biology methods and microscopic analyses, In previous studies, we suggested a relationship between we analyzed the expression of ezrin and PLC genes after PI-PLC expression and ezrin (17-18). -
The ELIXIR Core Data Resources: Fundamental Infrastructure for The
Supplementary Data: The ELIXIR Core Data Resources: fundamental infrastructure for the life sciences The “Supporting Material” referred to within this Supplementary Data can be found in the Supporting.Material.CDR.infrastructure file, DOI: 10.5281/zenodo.2625247 (https://zenodo.org/record/2625247). Figure 1. Scale of the Core Data Resources Table S1. Data from which Figure 1 is derived: Year 2013 2014 2015 2016 2017 Data entries 765881651 997794559 1726529931 1853429002 2715599247 Monthly user/IP addresses 1700660 2109586 2413724 2502617 2867265 FTEs 270 292.65 295.65 289.7 311.2 Figure 1 includes data from the following Core Data Resources: ArrayExpress, BRENDA, CATH, ChEBI, ChEMBL, EGA, ENA, Ensembl, Ensembl Genomes, EuropePMC, HPA, IntAct /MINT , InterPro, PDBe, PRIDE, SILVA, STRING, UniProt ● Note that Ensembl’s compute infrastructure physically relocated in 2016, so “Users/IP address” data are not available for that year. In this case, the 2015 numbers were rolled forward to 2016. ● Note that STRING makes only minor releases in 2014 and 2016, in that the interactions are re-computed, but the number of “Data entries” remains unchanged. The major releases that change the number of “Data entries” happened in 2013 and 2015. So, for “Data entries” , the number for 2013 was rolled forward to 2014, and the number for 2015 was rolled forward to 2016. The ELIXIR Core Data Resources: fundamental infrastructure for the life sciences 1 Figure 2: Usage of Core Data Resources in research The following steps were taken: 1. API calls were run on open access full text articles in Europe PMC to identify articles that mention Core Data Resource by name or include specific data record accession numbers. -
Volume 21 Supplement a December 2015 Next
EMBnet.journal Volume 21 Supplement A December 2015 Next Generation Sequencing: a look into the future Final Conference & MC Meeting of COST Action BM1006 16-17 March 2015 Bratislava, Slovakia http://seqahead.eu/bratislava_2015 ESF provides COST is supported the Cost Office by the EU RTD through an EC Framework contract Programme EDITORIAL/CONTENT EMBnet.journal 21.A Editorial Contents The key task of COST Action BM1006, SeqAhead, Editorial ..............................................................2 Next Generation Sequencing (NGS) Data Analysis COST Action BM1006 (SeqAhead) closing Network, was, as its name suggests, networking; conference ........................................................3 but SeqAhead also emphasised the dissemina- Scientific Programme.........................................5 tion of knowledge. During the four years of the Keynote Lectures ................................................9 Action, SeqAhead surpassed every expectation: Oral Presentations ........................................... 13 with members participating from 29 European Posters.......................................................................25 countries, plus one international partner from South Africa, the Management Committee mem- bership reads like a “who’s-who” of European NGS research. This EMBnet.journal Conference Supplement clearly shows that during the four years of SeqAhead’s existence, the Action members ac- tively shared software and experiences, and col- laborated in numerous projects spanning diverse EMBnet.journal -
From Genes to Genomes: Botanic Gardens Embracing New Tools for Conservation and Research Volume 18 • Number 1
Journal of Botanic Gardens Conservation International Volume 18 • Number 1 • February 2021 From genes to genomes: botanic gardens embracing new tools for conservation and research Volume 18 • Number 1 IN THIS ISSUE... EDITORS Suzanne Sharrock EDITORIAL: Director of Global Programmes FROM GENES TO GENOMES: BOTANIC GARDENS EMBRACING NEW TOOLS FOR CONSERVATION AND RESEARCH .... 03 Morgan Gostel Research Botanist, FEATURES Fort Worth Botanic Garden Botanical Research Institute of Texas and Director, GGI-Gardens NEWS FROM BGCI .... 06 Jean Linksy FEATURED GARDEN: THE NORTHWESTERN UNIVERSITY Magnolia Consortium Coordinator, ECOLOGICAL PARK & BOTANIC GARDENS .... 09 Atlanta Botanical Garden PLANT HUNTING TALES: GARDENS AND THEIR LESSONS: THE JOURNAL OF A BOTANY STUDENT Farahnoz Khojayori .... 13 Cover Photo: Young and aspiring scientists assist career scientists in sampling plants at the U.S. Botanic Garden for TALKING PLANTS: JONATHAN CODDINGTON, the Global Genome Initiative (U.S. Botanic Garden). DIRECTOR OF THE GLOBAL GENOME INITIATIVE .... 16 Design: Seascape www.seascapedesign.co.uk BGjournal is published by Botanic Gardens Conservation International (BGCI). It is published twice a year. Membership is open to all interested individuals, institutions and organisations that support the aims of BGCI. Further details available from: ARTICLES • Botanic Gardens Conservation International, Descanso House, 199 Kew Road, Richmond, Surrey TW9 3BW UK. Tel: +44 (0)20 8332 5953, Fax: +44 (0)20 8332 5956, E-mail: [email protected], www.bgci.org BANKING BOTANICAL BIODIVERSITY WITH THE GLOBAL GENOME • BGCI (US) Inc, The Huntington Library, BIODIVERSITY NETWORK (GGBN) Art Collections and Botanical Gardens, Ole Seberg, Gabi Dröge, Jonathan Coddington and Katharine Barker .... 19 1151 Oxford Rd, San Marino, CA 91108, USA. -
Data Integration and Handling
Data integration and handling Building an informatics platform for research integrated biobanks Tomas Klingström Faculty of Veterinary Medicine and Animal Science Department of Animal Breeding & Genetics Uppsala Doctoral thesis Swedish University of Agricultural Sciences Uppsala 2017 Acta Universitatis agriculturae Sueciae 2017:99 Cover: Photo of the equipment used to perform sequencing as a public display at the 40 year anniversary of the Swedish University of Agricultural Science. (photo: Erik Bongcam-Rudloff digital editing: Tomas Klingström) ISSN 1652-6880 ISBN (print version) 978-91-7760-088-6 ISBN (electronic version) 978-91-7760-089-3 © 2017 Tomas Klingström, Uppsala Print: SLU Service/Repro, Uppsala 2017 Data integration and handling: Building an informatics platform for research integrated biobanks Abstract Modern technology allows researchers to generate data at an ever increasing rate, outpacing the capacity of researchers to analyse it. Developing automated support systems for the collection, management and distribution of information is therefore an important step to reduce error rates and accelerate progress to enable high-quality research based on big data volumes. This thesis encompasses five articles, describing strategies for the creation of technical research platforms, as well as descriptions of the technical platforms themselves. The key conclusion of the thesis is that technical solutions for many issues have been available for a long time. These technical solutions are however overlooked, or simply ignored, if they fail to recognise the social dimensions of the issues they try to solve. The Molecular Methods database is an example of a technically sound but only partially successful solution in regards to social viability. Thousands of researchers have used the website to access protocols, but only a handful have shared their own work on MolMeth. -
Alteration in Phosphorylation of P20 Is Associated with Insulin Resistance Yu Wang,1 Aimin Xu,1 Jiming Ye,2 Edward W
Alteration in Phosphorylation of P20 Is Associated With Insulin Resistance Yu Wang,1 Aimin Xu,1 Jiming Ye,2 Edward W. Kraegen,2 Cynthia A. Tse,1 and Garth J.S. Cooper1,3 We have recently identified a small phosphoprotein, P20, insulin action, such as the activation of insulin receptors, as a common intracellular target for insulin and several postreceptor signal transduction, and the glucose trans- of its antagonists, including amylin, epinephrine, and cal- port effector system, have been implicated in this disease citonin gene-related peptide. These hormones elicit phos- (3,4). Defective insulin receptor kinase activity, reduced phorylation of P20 at its different sites, producing three insulin receptor substrate-1 tyrosine phosphorylation, and phosphorylated isoforms: S1 with an isoelectric point (pI) decreased phosphatidylinositol (PI)-3 kinase activity were value of 6.0, S2 with a pI value of 5.9, and S3 with a pI observed in both human type 2 diabetic patients as well as value of 5.6 (FEBS Letters 457:149–152 and 462:25–30, animal models, such as ob/ob mice (5,6). 1999). In the current study, we showed that P20 is one In addition to the intrinsic defects of the insulin receptor of the most abundant phosphoproteins in rat extensor digitorum longus (EDL) muscle. Insulin and amylin an- and postreceptor signaling components, other circulating tagonize each other’s actions in the phosphorylation of factors, such as tumor necrosis factor-␣, leptin, free fatty this protein in rat EDL muscle. Insulin inhibits amylin- acids, and amylin, may also contribute to the pathogenesis evoked phosphorylation of S2 and S3, whereas amylin of insulin resistance (7–11). -
Effective Angiogenesis Requires Regulation of Phosphoinositide Signaling
Effective angiogenesis requires regulation of phosphoinositide signaling Elizabeth Michele Davies, Rajendra Gurung, Kai Qin Le, Christina Anne Mitchell* Cancer Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Victoria 3800, Australia *Corresponding author [email protected] Abstract Phosphoinositide signaling regulates numerous downstream effectors that mediate cellular processes which influence cell cycle progression, migration, proliferation, growth, survival, metabolism and vesicular trafficking. A prominent role for phosphoinositide 3-kinase, which generates phosphatidylinositol 3,4,5-trisphosphate, a phospholipid that activates a plethora of effectors including AKT and FOXO during embryonic and postnatal angiogenesis, has been described. In addition, phosphatidylinositol 3-phosphate signaling is required for endosomal trafficking, which contributes to vascular remodeling. This review will examine the role phosphoinositide signaling plays in the endothelium and its contribution to sprouting angiogenesis. Keywords Angiogenesis, Phosphoinositide, PI3K, PTEN 1. Introduction Establishment of a functional vasculature is essential for embryonic development, and also for the maintenance of tissue regeneration, inflammatory responses and wound healing in the adult. Vascular development is characterized by two distinct physiological processes, vasculogenesis and angiogenesis. Vasculogenesis is predominantly limited to embryonic development, whereby differentiation -
Clinical Policy: Mecasermin (Increlex) Reference Number: ERX.SPA.209 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log
Clinical Policy: Mecasermin (Increlex) Reference Number: ERX.SPA.209 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Mecasermin (Increlex®) is an insulin growth factor-1 (IGF-1) analogue. FDA Approved Indication(s) Increlex is indicated for the treatment of growth failure in children with severe primary IGF-1 deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. Limitation(s) of use: Increlex is not a substitute to GH for approved GH indications. Policy/Criteria Provider must submit documentation (which may include office chart notes and lab results) supporting that member has met all approval criteria It is the policy of health plans affiliated with Envolve Pharmacy Solutions™ that Increlex is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Severe Primary IGF-1 Deficiency (must meet all): 1. Diagnosis of IGF-1 deficiency growth failure and associated growth failure with one of the following (a or b): a. Severe primary IGF-1 deficiency as defined by all (i through iii): i. Height standard deviation score (SDS) ≤ –3.0; ii. Basal IGF-1 SDS ≤ –3.0; iii. Normal or elevated GH level; b. GH gene deletion with development of neutralizing antibodies to GH; 2. Prescribed by or in consultation with an endocrinologist; 3. Age ≥ 2 and <18 years; 4. At the time of request, member does not have closed epiphyses; 5. Dose does not exceed 0.12 mg/kg twice daily. -
Insulin Products and the Cost of Diabetes Treatment
November 19, 2018 Insulin Products and the Cost of Diabetes Treatment Insulin is a hormone that regulates the storage and use of would involve a consistent insulin level between meals sugar (glucose) by cells in the body. When the pancreas combined with a mealtime level of insulin that has a rapid does not make enough insulin (type 1 diabetes) or it cannot onset and duration of action to match the glucose peak that be used effectively (type 2 diabetes), sugar builds up in the occurs after a meal. The original insulin, also called regular blood. This may lead to serious complications, such as heart insulin, is a short-acting type of product with a duration of disease, stroke, blindness, kidney failure, amputation of action of about 8 hours, making it less suitable for toes, feet, or limbs. Prior to the discovery of insulin providing 24-hour coverage. treatment, type 1 diabetics usually died from this disease. In the late 1930s through the 1950s, regular insulin was There were 23.1 million diagnosed cases of diabetes in the altered by adding substances (protamine and zinc) to gain United States in 2015 according to the Centers for Disease longer action; these are called intermediate-acting insulins. Control and Prevention (CDC). Adding an estimated 7.2 One such advance (neutral protamine Hagedorn, or NPH) million undiagnosed cases brings the total to 30.3 million was patented in 1946 and is still in use today. It allowed for (9.4% of U.S. population). People with type 1 diabetes, the combination of two types of insulin in premixed vials about 5% of U.S. -
Single-Cell Analysis of Crohn's Disease Lesions Identifies
bioRxiv preprint doi: https://doi.org/10.1101/503102; this version posted December 20, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Single-cell analysis of Crohn’s disease lesions identifies a pathogenic cellular module associated with resistance to anti-TNF therapy JC Martin1,2,3, G Boschetti1,2,3, C Chang1,2,3, R Ungaro4, M Giri5, LS Chuang5, S Nayar5, A Greenstein6, M. Dubinsky7, L Walker1,2,5,8, A Leader1,2,3, JS Fine9, CE Whitehurst9, L Mbow9, S Kugathasan10, L.A. Denson11, J.Hyams12, JR Friedman13, P Desai13, HM Ko14, I Laface1,2,8, Guray Akturk1,2,8, EE Schadt15,16, S Gnjatic1,2,8, A Rahman1,2,5,8, , M Merad1,2,3,8,17,18*, JH Cho5,17,*, E Kenigsberg1,15,16,17* 1 Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. 2 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. 3 Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. 4 The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York City, NY 10029, USA. 5 Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. 6 Department of Colorectal Surgery, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA 7 Department of Pediatrics, Susan and Leonard Feinstein IBD Clinical Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.